{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T00:03:33Z","timestamp":1793750613740,"version":"4.6.1"},"reference-count":23,"publisher":"Cambridge University Press (CUP)","issue":"5","license":[{"start":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:00:00Z","timestamp":1539216000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec id=\"S1092852918001086_abs1\"><jats:title>Objective<\/jats:title><jats:p>To compare the tolerability and efficacy of different antipsychotic cross-titration schedules, using data from a brexpiprazole study (Equator; NCT01668797).<\/jats:p><\/jats:sec><jats:sec id=\"S1092852918001086_abs2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>Patients with schizophrenia were cross-titrated from other antipsychotics to brexpiprazole monotherapy in a 1\u20134 week open-label conversion phase, then entered a single-blind brexpiprazole treatment phase. Patients were stratified into four \u201cconversion groups,\u201d according to the amount of time spent in the conversion phase. Discontinuation rates, treatment-emergent adverse events (TEAEs), and efficacy (Positive and Negative Syndrome Scale [PANSS]) were compared between conversion groups.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852918001086_abs3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Of the 404 patients treated with brexpiprazole, the majority (72.0%) spent 22\u201333 days in the conversion phase. Discontinuation rates due to lack of efficacy or adverse events were low in all conversion groups. Of the 292 patients who successfully switched and completed 8 weeks of brexpiprazole treatment, most were converted to brexpiprazole over 22\u201333 days (80.1%), and fewer were converted over 1\u20137 days (2.4%), 8\u201314 days (6.5%), or 15\u201321 days (11.0%). The incidence of TEAEs over 8 weeks was lower among those converted over 22\u201333 days (44.4%) than in other conversion groups (62.5\u201384.2%), although low patient numbers with shorter conversion times limit the generalizability of this finding. Each conversion group showed comparable improvement in PANSS total score from baseline.<\/jats:p><\/jats:sec><jats:sec id=\"S1092852918001086_abs4\" sec-type=\"conclusion\"><jats:title>Conclusion<\/jats:title><jats:p>The majority of patients were cross-titrated to brexpiprazole over a period of 22\u201333 days, by investigators\u2019 choice. Additional data on shorter conversions may help clinicians to choose a switching paradigm that best meets their patients\u2019 needs.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s1092852918001086","type":"journal-article","created":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T07:23:15Z","timestamp":1539242595000},"page":"507-517","source":"Crossref","is-referenced-by-count":14,"title":["Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians\u2019 choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study"],"prefix":"10.1017","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U.","family":"Correll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Hobart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Eramo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth A.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Weiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2018,10,11]]},"reference":[{"key":"S1092852918001086_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2015.01.038"},{"key":"S1092852918001086_ref2","first-page":"4","article-title":"Strategies for dosing and switching antipsychotics for optimal clinical management","volume":"69","author":"Buckley","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"S1092852918001086_ref17","volume-title":"ECDEU Assessment Manual for Psychopharmacology, Revised","author":"Guy","year":"1976"},{"key":"S1092852918001086_ref16","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"S1092852918001086_ref15","unstructured":"Sheehan D , Janavs J , Harnett-Sheehan K , et al. Mini International Neuropsychiatric Interview (MINI) for Schizophrenia and Psychotic Disorders Studies, Version 6.0.0. 2010. Copyright 1992\u20132010 Sheehan DV & Lecrubier Y. https:\/\/www.psychcongress.com\/saundras-corner\/scales-screeners\/structured-diagnostic-interview-instruments\/mini-screen-600"},{"key":"S1092852918001086_ref1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519010-00003"},{"key":"S1092852918001086_ref7","first-page":"5","article-title":"Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary","volume":"64","author":"Kane","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"S1092852918001086_ref22","first-page":"862","article-title":"Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis","volume":"43","author":"Takeuchi","year":"2017","journal-title":"Schizophr Bull"},{"key":"S1092852918001086_ref3","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-10-75"},{"key":"S1092852918001086_ref4","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12028ah1"},{"key":"S1092852918001086_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(10)71701-6"},{"key":"S1092852918001086_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2017.02.011"},{"key":"S1092852918001086_ref5","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0122"},{"key":"S1092852918001086_ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2017.08.012"},{"key":"S1092852918001086_ref14","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2000"},{"key":"S1092852918001086_ref10","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.213793"},{"key":"S1092852918001086_ref19","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15032su1"},{"key":"S1092852918001086_ref11","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.14101275"},{"key":"S1092852918001086_ref13","first-page":"11","article-title":"Efficacy and safety of brexpiprazole (OPC-34712) as maintenance treatment in adults with schizophrenia: a randomised, double-blind, placebo-controlled study","volume":"20","author":"Fleischhacker","year":"2017","journal-title":"Int J Neuropsychopharmacol"},{"key":"S1092852918001086_ref6","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852900027693"},{"key":"S1092852918001086_ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1344-3"},{"key":"S1092852918001086_ref18","first-page":"S15","article-title":"Switching approach in the management of schizophrenia patients","volume":"15","author":"Peuskens","year":"2000","journal-title":"Int Clin Psychopharmacol"},{"key":"S1092852918001086_ref20","doi-asserted-by":"publisher","DOI":"10.4321\/S0213-61632012000100004"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852918001086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T23:10:03Z","timestamp":1569885003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852918001086\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,11]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1092852918001086"],"URL":"https:\/\/doi.org\/10.1017\/s1092852918001086","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,11]]}}}